Tuesday, June 30, 2026

VisionWave (Nasdaq: $VWAV) Strikes $20.4 Million Deal to Acquire 51% of Israeli Defense Leader Meteor Aerospace; @VWAVInc

 

VisionWave (Nasdaq: $VWAV) Strikes $20.4 Million Deal to Acquire 51% of Israeli Defense Leader Meteor Aerospace; @VWAVInc




 

 


 

Investorideas.com, a trusted investment site for retail Investors following AI and defense stocks, reports on breaking news and trading for VisionWave Holdings, Inc (Nasdaq: VWAV), a defense technology company developing advanced artificial intelligence, autonomous systems and next-generation security technologies.

 

VisionWave Holdings, Inc. (Nasdaq: VWAV)  today announced that it has entered into a definitive binding agreement to acquire a 51% controlling interest in Meteor Aerospace Ltd., a privately held Israeli aerospace and defense company recognized for its portfolio of advanced unmanned systems, precision defense technologies and integrated national security solutions.

Why this matters -Proposed Acquisition Would Expand VisionWave into Advanced Unmanned Systems, Electronic Warfare, C4ISR and National Defense Architecture Solutions

 

Investorideas .com – why this matters to the sector?  This acquisition is strategically significant because it positions VisionWave (VWAV) in several of the fastest-growing, highest-priority segments of the global defense market: unmanned systems (UAVs/UGVs/USVs), electronic warfare (EW), SIGINT, and C4ISR (Command, Control, Communications, Computers, Intelligence, Surveillance, Reconnaissance). marketsandmarkets.com

 

Under the agreement, Meteor Aerospace is valued at a pre-money equity valuation of $40 million. Upon satisfaction of customary closing conditions, including successful flight validation of Meteor’s Impact-700 unmanned aerial platform and completion of legal, financial and technical due diligence, VisionWave will acquire 51% of Meteor through the issuance of VisionWave common stock having an aggregate value of approximately $20.4 million.

 

Paid News Dissemination on behalf of VWAV 

 

Read this news, featuring VWAV in full at https://www.investorideas.com/CO/VWAV/news/2026/06301-visionwave-acquires-51pct-meteor-aerospace.asp

 

Founded by Itzhak Nissan, former President and Chief Executive Officer of Israel Aerospace Industries (IAI), Meteor Aerospace has developed a diversified portfolio of aerospace and defense technologies, including:

  • Tactical and strategic unmanned aerial vehicles (UAVs);
  • Unmanned ground vehicles (UGVs);
  • Unmanned surface vessels (USVs);
  • Long-range precision loitering munition systems;
  • Electronic warfare (EW) and SIGINT technologies;
  • Command, Control, Communications, Cyber and Battlefield Management (C4ISR) systems;
  • Integrated sovereign defense and homeland security architectures.

 

Unlike traditional defense manufacturers focused on a single product category, Meteor has positioned itself as an integrated defense technology company capable of delivering complete multi-domain operational solutions spanning air, land, sea and electronic warfare environments.

 

Upon completion of the transaction, VisionWave expects to obtain a controlling interest in Meteor Aerospace, appoint a majority of its Board of Directors and integrate Meteor’s technologies into VisionWave’s rapidly expanding global defense technology platform.

The agreement also provides for the continued involvement of Meteor founder Itzhak Nissan, who is expected to continue leading Meteor’s technological activities following closing as Chief Technology Director.

 

Douglas Davis, Executive Chairman and Chief Executive Officer of VisionWave, stated:

“This agreement represents and the proposed transaction will represent a significant strategic milestone in VisionWave’s history assuming we are able to close the transaction. This proposed transaction just does not represent another defense company—we would be adding decades of aerospace engineering excellence, advanced autonomous platforms, electronic warfare capabilities, battlefield command-and-control technologies and a highly experienced management team with an exceptional heritage in the global defense industry.”

 

Mr. Davis continued:

“Combined with VisionWave’s existing artificial intelligence, advanced sensing and defense technology initiatives, we believe this transaction has the potential to create a diversified defense technology platform capable of addressing rapidly growing global demand for autonomous systems, integrated battlefield solutions and sovereign security modernization.”

The proposed acquisition remains subject to customary closing conditions, including successful completion of the agreed flight validation – which is a material event, satisfactory due diligence and other conditions contained in the definitive acquisition agreement. There can be no assurance that the transaction will be completed on the terms described, or at all.

 

About VisionWave Holdings, Inc.

VisionWave Holdings, Inc. (Nasdaq: VWAV) is a defense and advanced sensing technology company developing AI-driven, RF-based sensing, autonomy, and computational acceleration technologies for defense, homeland security, and commercial infrastructure applications. VisionWave's mission is to connect defense innovation with civilian progress through shared core technologies deployed across air, land, and fixed-site environments. The Company's website is https://www.vwav.inc

 

About Meteor Aerospace Ltd.

Meteor Aerospace Ltd. is an Israeli aerospace and defense company specializing in advanced unmanned aerial, ground and maritime systems, electronic warfare technologies, precision strike solutions, C4ISR systems and integrated sovereign defense architecture. The company was founded by Itzhak Nissan, former President and Chief Executive Officer of Israel Aerospace Industries. Meteor Aerospace Ltd website is: https://www.m-aerospace.com/

 

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding the proposed acquisition by VisionWave Holdings, Inc. (“VisionWave” or the “Company”) of a 51% controlling interest in Meteor Aerospace Ltd. (“Meteor”); the anticipated timing and completion of the transaction; the satisfaction of the conditions to closing, including the successful completion of the flight validation of the Meteor Impact 700; the expected benefits, strategic rationale and synergies of the transaction; the integration of Meteor’s products, technologies and personnel; the Company’s future operations, growth and expansion; and the Company’s intended use of the acquired technologies. These statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially. Forward-looking statements are generally identified by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “project,” “forecast,” “predict,” and similar expressions, or by statements that events or trends “may,” “will,” or “could” occur.

 

Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including, but not limited to, the failure to successfully complete the flight validation of the Meteor Impact 700, which is a binding condition to closing; the failure to satisfy or waive the other conditions to closing, including the satisfactory completion of the Company’s legal, financial, operational, technical, aerospace, cybersecurity, export-control, intellectual property and commercial due diligence; the risk that the transaction is not completed on the anticipated timeline or at all; the share-based nature of the consideration, the determination of the number of shares issuable based on the volume weighted average price of VisionWave common stock prior to closing, and the resulting dilution to existing stockholders; risks relating to the resale of, and the contractual lock-up applicable to, the shares to be issued; the failure to obtain required regulatory, governmental and export-control approvals under applicable U.S. and Israeli law; risks associated with integrating Meteor’s business, technologies and personnel; the Company’s ability to retain key personnel, including Meteor’s founder; risks of operating in Israel and in the global defense and aerospace industry, including geopolitical, security, regulatory and supply-chain conditions; the results of due diligence and the accuracy of the representations made to the Company; the Company’s need for, and ability to obtain, additional capital; and general economic, market and industry conditions, and other risks described in the Company’s filings with the U.S. Securities and Exchange Commission. All forward-looking statements speak only as of the date of this press release and are expressly qualified in their entirety by the cautionary statements included in this press release and in the Company’s SEC filings. VisionWave undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Investors are cautioned not to place undue reliance on these forward-looking statements.

 

Contact: investors@vwav.inc

VisionWave Holdings is a Featured Defense stock on Investorideaas.om

https://www.investorideas.com/CO/VWAV/



Research more defense stocks at Investorideas stock directory

https://www.investorideas.com/Companies/HomelandDefense/stock_list.asp

 




Disclaimer/Disclosure: VisionWave Holdings, Inc. is a paid for featured defense company on Investorideas.com. Investorideas is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. Contact management and IR of each company directly regarding specific questions.
More disclaimer info:  Learn more about publishing your news release and our other news services on the Investorideas.com newswire. Global investors must adhere to regulations of each country. Please read Investorideas.com privacy policy:
https://www.investorideas.com/About/Private_Policy.asp

 

About Investorideas.com - Where you find the best investing ideas

Investorideas.com is a trusted platform for retail investors, serving as a hub for innovative investing ideas for over 25 years. Known for its pioneering coverage of sectors like mining, cleantech, defense, and water stocks, the company and its executives have been featured in high-profile media outlets for its expertise. Investorideas.com is always at the forefront of investment trends, offering coverage of diverse industries such as Al, mining, and tech. With a mission to empower investors, the company provides breaking news, sector-focused articles, podcasts, and exclusive interviews with leading experts. In addition, its award-winning branded content, Al-driven short videos, and podcasts highlight key investing insights and feature prominent industry leaders.

 

Advertising agencies -Learn more about digital advertising and guest posts at Investorideas

https://www.investorideas.com/Advertise/

 

Follow & Contact

Follow us on X: @investorideas

Follow us on Facebook https://www.facebook.com/Investorideas

Follow us on YouTube @Investorideas

 

 

 

 

 

 

 

 

 

 

Friday, June 26, 2026

Biotech's Rapid Response to the 2026 Ebola Outbreak: Vaccines, Antibodies, and Therapeutics Advance

 

Biotech's Rapid Response to the 2026 Ebola Outbreak: Vaccines, Antibodies, and Therapeutics Advance

 

Stocks Mentitoned: (Nasdaq: $AEMD), (NASDAQ:$SNGX), (NASDAQ: $REGN), (NASDAQ:$MRNA)  

 



 

(Investorideas.com Newswire) Investorideas.com, a leading investment platform for retail investors releases an editorial snapshot on biotech and medical tech stocks announcing potential treatments and vaccines for the 2026 Ebola virus outbreak. 

According to a recent ABC news headline - “France confirms 1st Ebola case linked to DRC as UN warns outbreak is fastest-growing in Africa's history. The outbreak has led to more than 1,000 cases and more than 260 deaths.”

 

UN news reports – “Ebola has been spreading at unprecedented speed in the eastern Democratic Republic of the Congo (DRC), bringing risk and fear into people’s daily lives, UN humanitarians said on Tuesday.”

 

From big pharma to smaller players, stocks in the sector are making headlines as the outbreak continues. Biotech and biodefense stocks focusing on infectious diseases like Ebola can be highly speculative and the sector has already experienced volatility.  

 

Paid News Dissemination of behalf of AEMD

Read this news, featuring AEMD in full at https://www.investorideas.com/CO/AEMD/news/2026/06261-biotech-ebola-vaccines-therapeutics.asp   

 

Soligenix (NASDAQ:SNGX) a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, reported June 8th that the Coalition for Epidemic Preparedness Innovations (CEPI) has announced a call for proposal for vaccine development for Bundibugyo virus (BDBV) with applications due June 12, 2026. Soligenix, in collaboration with Axel Lehrer, PhD, Professor in the Department of Tropical Medicine, Medical Microbiology and Pharmacology at the John A. Burns School of Medicine, University of Hawaiʻi at Mānoa, has previously developed bivalent and trivalent thermostable vaccines, constructed from antigens against Ebola virus, Sudan virus and Marburg virus and the CoVaccine HT™ adjuvant, demonstrating thermostability,

immunogenicity and durable efficacy in non-human primates. This work, combined with previous and ongoing work in Dr. Lehrer's laboratory that has demonstrated platform compatibility of the key Bundibugyo virus antigen, will form the basis of an application to CEPI enabling rapid development of a protein-based thermostable subunit vaccine for BDBV.

 

From the news:

"Our filovirus vaccines have demonstrated broad and robust immune responses in mice and up to 100% protection in non-human primates," stated Dr. Lehrer. "Further, we have developed thermostable vaccine formulations in collaboration with Soligenix, demonstrating extended stability that is particularly relevant for the use of these vaccines in virus-endemic countries in Africa, as well as in the context of strategic national stockpiles and preparations for potential larger outbreaks and pandemics. A single-vial subunit vaccine that can be shipped at ambient temperatures and then needs to only be reconstituted with sterile water immediately prior to use has the potential to improve vaccination efforts globally by simplifying storage and distribution logistics not only as a stand-alone vaccine, but also as a practical add-on booster broadening immunity in persons previously or concurrently vaccinated with other vaccines. We look forward to submitting this application with the aim of rapidly advancing the BDBV vaccine and the multivalent platform in general."

 

Aethlon Medical, Inc. (Nasdaq: AEMD), a medical therapeutic company focused on developing products to treat cancer and life-threatening infectious diseases recently announced that it is actively monitoring developments related to the current Bundibugyo Ebola virus outbreak in Democratic Republic of the Congo and Uganda, and remains prepared to engage with global healthcare and regulatory authorities regarding the potential investigational use of its Hemopurifier® technology.

 

Aethlon’s Hemopurifier is an investigational medical device designed to remove enveloped viruses and tumor-derived EVs from circulation. During the 2014 Ebola (Zaire strain) outbreak, the Hemopurifier was successfully administered to a critically ill Ugandan physician treated at Frankfurt University Hospital under emergency-use circumstances.

 

At the time Hemopurifier therapy was initiated, the physician was unconscious and suffering from multiple organ failure requiring mechanical ventilation, vasopressor support and continuous dialysis. Following a single 6.5-hour Hemopurifier treatment, the patient’s viral load reportedly declined from approximately 400,000 Ebola virus copies per milliliter of blood to approximately 1,000 copies per milliliter of blood. The Ebola virus subsequently became undetectable five days following treatment. Testing performed after this treatment indicated that the Hemopurifier captured Ebola virus during therapy; quantitative estimates reported at the time, were approximately 242 million virions. The patient ultimately made recovered and returned home to Uganda.

 

In its recent earnings conference call, Aethlon noted that it has shared information regarding its Ebola-related research, clinical experience, and regulatory status with the World Health Organization's R&D Blueprint Expert Panel and the National Emerging Special Pathogens Training and Education Center (NETEC), which works closely with the 13 U.S. regional special pathogen treatment centers that would treat an Ebola patient in the United States should one occur.

 

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced in May that maftivimab, the most potent neutralizing antibody included in Inmazeb® (maftivimab, atoltivimab and odesivimab-ebgn), has been recommended by the World Health Organization’s (WHO) Therapeutics Advisory Group to be prioritized for evaluation in clinical trials of investigational treatments for Bundibugyo ebolavirus. Maftivimab has demonstrated broad activity in vitro against multiple Ebola species, including Bundibugyo.

 

From the news:

The trial pertains to the WHO’s recent declaration that the current outbreak of Ebola disease caused by Bundibugyo virus in the Democratic Republic of the Congo (DRC) and Uganda constitutes a public health emergency of international concern. WHO is now working closely with the governments of DRC and Uganda to facilitate the implementation of research evaluations of the prioritized products.

 

“We are closely coordinating our efforts with the U.S. Department of Health and Human Services (HHS) and look forward to working with the World Health Organization and others as clinical evaluation moves ahead,” said Leonard S. Schleifer, M.D., Ph.D., Board co-Chair, President and Chief Executive Officer of Regeneron. “Regeneron has a track record of rapidly delivering important medical solutions during times of global health crisis, such as the COVID-19 pandemic and multiple Ebola outbreaks, and we know that independently run and locally executed clinical trials are critical to developing effective new medicines in such situations.”

 

Inmazeb is already approved by the U.S. Food and Drug Administration for the treatment of infection caused by Orthoebolavirus zairense, also known as Zaire ebolavirus, in adult and pediatric patients, including neonates born to infected mothers. Maftivimab is the most potent virus-neutralizing component of Inmazeb and has demonstrated broad neutralizing activity in laboratory studies against Bundibugyo ebolavirus; it has not yet been tested in vivo as a monotherapy against this distinct Ebola virus. Maftivimab has been administered to hundreds of human patients as a component of Inmazeb, which has demonstrated an acceptable safety profile. Since 2018, Inmazeb has been offered by Regeneron at no cost under a compassionate use protocol to infected persons in countries experiencing an Orthoebolavirus zairense outbreak, including the DRC and Guinea.

 

On June 1, Moderna, Inc. (NASDAQ:MRNA)  announced an expanded collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of a potential vaccine against Bundibugyo ebolavirus (BDBV), a cause of Ebola virus disease for which there are currently no licensed vaccines indicated.

 

From the news:

Under the agreement, CEPI has committed up to US $50 million to support preclinical development and Phase 1 clinical testing of Moderna's investigational BDBV vaccine candidate. The funding will also support parallel manufacturing activities, enabling doses to be produced while clinical evaluation is underway and positioning the program to rapidly advance into large-scale Phase 2/3 trials should the Phase 1 safety and immunogenicity data support further development.

 

The vaccine candidate is being developed using Moderna's mRNA platform, the same technology that demonstrated rapid development, scalability, and global deployment capabilities during the COVID-19 pandemic. The program also builds on Moderna's existing research and development efforts in filoviruses, including Ebola-related viruses.

 

The collaboration further expands Moderna's longstanding strategic collaboration with CEPI, which is focused on accelerating the development of vaccines and other countermeasures against epidemic and pandemic threats.

 

"At Moderna, we believe our mRNA platform can play an important role in responding rapidly to emerging infectious disease threats," said Stéphane Bancel, Chief Executive Officer of Moderna. "We are proud to expand our strategic collaboration with CEPI to advance a potential vaccine candidate against Bundibugyo ebolavirus, leveraging our established technology and experience in filovirus vaccine development. We will move with urgency and scientific rigor to support the response and help bring a potential vaccine closer to the communities that need it most."

 

By combining CEPI's funding and expertise in epidemic preparedness with Moderna's mRNA platform and manufacturing capabilities, the collaboration aims to accelerate the development of a potential vaccine that could help strengthen global readiness against future Ebola outbreaks.

 

"With Bundibugyo virus spreading rapidly and no licensed vaccines, every day counts in the race against this deadly disease," said Dr. Richard Hatchett, CEO of CEPI. "CEPI's urgent funding and support aims to advance safe, effective vaccines to help control this epidemic."

 

Disclaimer/Disclosure: Disclaimer: Biotech and biodefense stocks focusing on infectious diseases can be highly speculative and carry significant volatility. Aethlon Medical, Inc. (AEMD) is a paid featured medical tech stock on Investor ideas More disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. More disclosure: Contact management and IR of each company directly regarding specific questions.

 

 


Research biotech stocks at Investorideas.com:

https://www.investorideas.com/Companies/RenewableEnergy/stock_list.asp

 

 

 

 

About Investorideas.com – Where you find the best investing ideas

Investorideas.com is a trusted platform for retail investors, serving as a hub for innovative investing ideas for over 25 years. Known for its pioneering coverage of sectors like mining, cleantech, defense, and water stocks, the company and its executives have been featured in high-profile media outlets for its expertise. Investorideas.com is always at the forefront of investment trends, offering coverage of diverse industries such as Al, mining, and tech. With a mission to empower investors, the company provides breaking news, sector-focused articles, podcasts, and exclusive interviews with leading experts. In addition, its award-winning branded content, Al-driven short videos, and podcasts highlight key investing insights and feature prominent industry leaders.

 

Investor Ideas digital advertising and guest posts service :

https://www.investorideas.com/Advertise/

 

Follow us on X @investorideas @stocknewsbites

Follow us on Facebook https://www.facebook.com/Investorideas

Follow Investorideas on YouTube https://www.youtube.com/c/Investorideas

 

 

Join our free Telegram community

https://t.me/+o8DxSAgeNCk2ZGVh

 

Contact us for more info  

Call 800 665 0411

Breakthrough Long COVID Biomarker Identified by Aethlon Medical (Nasdaq: $AEMD) Opens Door for Hemopurifier Treatment

 

Breakthrough Long COVID Biomarker Identified by Aethlon Medical (Nasdaq: $AEMD) Opens Door for Hemopurifier Treatment

 



 

 



(Investorideas.com Newswire) Investorideas.com, a trusted investment platform for retail investors reports breaking Medical Tech Stock news for  Aethlon Medical, Inc. (Nasdaq: AEMD), a clinical-stage medical therapeutic company focused on developing products to treat cancer and life-threatening viral infections for which there is no treatment.

Aethlon Medical, Inc. (Nasdaq: AEMD),today announced publication of new peer-reviewed research in the International Journal of Molecular Sciences demonstrating that patients with Long COVID exhibit significantly increased levels of mannosylated extracellular vesicles (EVs) that can be captured using the same Galanthus nivalis agglutinin (GNA) affinity resin incorporated into the Company's Hemopurifier®.

Peer-reviewed study identifies altered extracellular vesicles in Long COVID and provides additional scientific rationale for evaluating the Hemopurifier® as a potential treatment

The study, conducted in collaboration with investigators from the University of California, San Francisco (UCSF), provides what we believe is new evidence supporting extracellular vesicles as a potential therapeutic target in Long COVID and helps establish a translational framework for future studies evaluating whether the Hemopurifier can remove disease-associated EVs and their molecular cargo.

Paid News Dissemination of behalf of AEMD

Read this news, featuring AEMD in full at https://www.investorideas.com/CO/AEMD/news/2026/06262-long-covid-biomarker-hemopurifier-aemd.asp

"The publication of this study contributes to the scientific understanding of the biological mechanisms underlying Long COVID while strengthening the rationale for evaluating the Hemopurifier in this significant area of unmet medical need," said Jim Frakes, Chief Executive Officer and Chief Financial Officer of Aethlon Medical. “While the Company’s current resources and primary focus remain dedicated to advancing our Australian oncology clinical trial, these findings provide additional translational evidence supporting future preclinical and clinical studies designed to determine whether removal of these circulating extracellular vesicles may benefit patients with Long COVID.  More broadly, we believe these findings reinforce the potential of the Hemopurifier as a platform technology with potential applications across multiple disease areas.  We believe there exists a ‘pipeline within a single device.’”

Key Findings

Among the study's principal findings:

      Patients with Long COVID had approximately two-fold higher levels of mannose-positive extracellular vesicles than individuals who recovered fully following COVID-19 infection.

      Small extracellular vesicles carrying disease-associated glycosylation patterns were successfully captured using GNA affinity resin, the active binding component of the Hemopurifier.

      GNA affinity resin treatment significantly reduced seven circulating microRNAs associated with immune regulation and inflammatory signaling.

      Computational pathway analysis suggested modulation of several biologically relevant signaling pathways implicated in Long COVID, including JAK-STAT, VEGF, PI3K, and Estrogen signaling.

      The findings help establish a mechanistic link between disease-associated extracellular vesicles and the Hemopurifier's lectin-based capture technology.

The research analyzed plasma samples from participants enrolled in UCSF's Long-term Impact of Infection with Novel Coronavirus (LIINC) study.

The full peer-reviewed article, titled "Increased Mannosylation of Extracellular Vesicles in Long COVID Plasma as a Binding Target for Galanthus nivalis Agglutinin (GNA) Affinity Resin," appears in the International Journal of Molecular Sciences at https://www.mdpi.com/1422-0067/27/13/5723

About Aethlon and the Hemopurifier®
Aethlon Medical is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device that is designed to combat cancer and life-threatening viral infections, and for use in organ transplantation. In human studies, the Hemopurifier has demonstrated the removal of life-threatening viruses, and in pre-clinical studies, the Hemopurifier has demonstrated the removal of harmful EVs from biological fluids, utilizing its proprietary lectin-based technology. This action has potential applications in cancer, where EVs may promote immune suppression and metastasis, and in life-threatening infectious diseases. The Hemopurifier is a U.S. Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which EVs have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption (IDE) application related to the treatment of life-threatening viruses that are not addressed with approved therapies.

Additional information can be found at www.AethlonMedical.com.

 

Aethlon Medical, Inc. (Nasdaq: AEMD is a featured biotech stock on Investorideas.com

 

More info on AEMD at Investorideas.com Visit: https://www.investorideas.com/CO/AEMD/

Get News Alerts on Aethlon Medical

 

Disclaimer/Disclosure: Aethlon Medical, Inc. is a paid featured medical tech stock on Investor ideas More disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. More disclosure: Contact management and IR of each company directly regarding specific questions.

 


Research biotech stocks at Investorideas.com:

https://www.investorideas.com/Companies/RenewableEnergy/stock_list.asp

 

 

 



About Investorideas.com – Where you find the best investing ideas

Investorideas.com is a trusted platform for retail investors, serving as a hub for innovative investing ideas for over 25 years. Known for its pioneering coverage of sectors like mining, cleantech, defense, and water stocks, the company and its executives have been featured in high-profile media outlets for its expertise. Investorideas.com is always at the forefront of investment trends, offering coverage of diverse industries such as Al, mining, and tech. With a mission to empower investors, the company provides breaking news, sector-focused articles, podcasts, and exclusive interviews with leading experts. In addition, its award-winning branded content, Al-driven short videos, and podcasts highlight key investing insights and feature prominent industry leaders.

Investor Ideas digital advertising and guest posts service :

https://www.investorideas.com/Advertise/

 

Follow us on X @investorideas @stocknewsbites

Follow us on Facebook https://www.facebook.com/Investorideas

 

Follow Investorideas and the Exploring Mining Podcast on YouTube https://www.youtube.com/c/Investorideas

 

Investors stay ahead by signing up for free stock news alerts at Investorideas.com

https://www.investorideas.com/Resources/Newsletter.asp

 

Join our free Telegram community

https://t.me/+o8DxSAgeNCk2ZGVh

 

Contact us for more info  

Call 800 665 0411